MedTrace Logo

A Clinical Study Evaluating Efficacy of Pirepemat on Falls Frequency in Patients with Parkinson's Disease (PD)

NCT05258071 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 104

Last updated 2025-01-27

No results posted yet for this study

Summary

This is a Phase 2b study investigating the efficacy and safety of pirepemat as adjunct therapy on falls frequency in patients with Parkinson disease. Pirepemat is taken for 84 days.

Conditions

  • Parkinson Disease

Interventions

DRUG

Pirepemat

Oral use

DRUG

Placebo

Oral use

Sponsors & Collaborators

  • Integrative Research Laboratories AB

    lead INDUSTRY

Principal Investigators

  • Joakim Tedroff · Integrative Research Laboratories AB

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-15
Primary Completion
2024-12-04
Completion
2025-01-09

Countries

  • France
  • Germany
  • Netherlands
  • Poland
  • Spain
  • Sweden

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05258071 on ClinicalTrials.gov